Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vital Signs

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5,436 result(s) found for: Vital Signs. Displaying page 60 of 272.
    «« First « Previous 56  57  58  59  60  61  62  63  64  Next» Last»»
    EudraCT Number: 2012-002917-20 Sponsor Protocol Number: JAK116679 Start Date*: 2012-12-11
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis
    Medical condition: chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050577 Psoriatic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004886-42 Sponsor Protocol Number: TRA114389 Start Date*: 2013-04-01
    Sponsor Name:University of Crete
    Full Title: Study of the effect of the thrombopoietin receptor agonist eltrombopag on thrombocytopenia and megakaryopoiesis of patients with lower and intermediate-1 risk myelodysplastic syndromes.
    Medical condition: Patients with lower and intermediate-1 risk myelodysplastic syndromes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000790-21 Sponsor Protocol Number: ESR-15-10862 Start Date*: 2017-01-04
    Sponsor Name:Radboudumc
    Full Title: Effect of the GLP-1 receptor agonist exenatide on impaired hypoglycaemic awareness in type 1 diabetes
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002055-28 Sponsor Protocol Number: SK-DMDPA-02 Start Date*: 2017-10-13
    Sponsor Name:Synektik Spółka Akcyjna
    Full Title: Safety and dose optimization for [11C] DMDPA as a PET imaging agent for evaluation of myocardial perfusion in subjects with known or suspected coronary artery disease (CAD).
    Medical condition: known or suspected coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001448-75 Sponsor Protocol Number: OPT-80-206 Start Date*: 2014-09-15
    Sponsor Name:Optimer Pharmaceutical, Inc. (a Cubist company)
    Full Title: A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridiu...
    Medical condition: Clostridium difficile infections (CDI), also known as Clostridium difficile- associated diarrhea
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10012748 Diarrhoea, Clostridium difficile LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002487-41 Sponsor Protocol Number: GLY-321-2017 Start Date*: 2018-01-31
    Sponsor Name:GLyPharma Therapeutic Inc. (a wholly owned subsidiary of VectivBio Holding AG)
    Full Title: A Phase Ib/IIa open-label, repeated dose, metabolic balance study of FE 203799 in patients with short bowel syndrome
    Medical condition: Short bowel syndrome (SBS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-000114-22 Sponsor Protocol Number: CQVA149A2316 Start Date*: 2015-09-02
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 26-week, randomized, double blind, parallel-group multicenter study to assess the efficacy and safety of QVA149 (110/50 μg o.d.) vs tiotropium (18 μg o.d.) + salmeterol/fluticasone propionate FDC...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) EE (Completed) NL (Completed) LV (Completed) LT (Completed) DE (Completed) CZ (Completed) HU (Completed) DK (Completed) SK (Completed) ES (Completed) AT (Completed) PL (Completed) GR (Completed) HR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-002237-22 Sponsor Protocol Number: MK-0518B-196 Start Date*: 2015-05-22
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Study to Compare the Pharmacokinetics of a Fixed-Dose Combination of Raltegravir and Lamivudine to Co-administered Raltegravir and Lamivudine
    Medical condition: HIV-1 Infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003269-16 Sponsor Protocol Number: GS-US-320-1196 Start Date*: 2019-08-30
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1, Single-Dose, Cross-Over Study Evaluating the Relative Bioavailability of a Pediatric Oral Granule Formulation of Tenofovir Alafenamide in Healthy Adults
    Medical condition: Chronic Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001974-32 Sponsor Protocol Number: CAIN457ADE04 Start Date*: 2015-04-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, double-blind, multicenter study to assess the efficacy and safety of 16 weeks secukinumab dosage interval shortening (2-weekly 300 mg s.c.) in comparison to continued standard treatme...
    Medical condition: chronic moderate to severe plaque type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000671-34 Sponsor Protocol Number: CVAA489A2305 Start Date*: 2005-01-14
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsart...
    Medical condition: hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) LV (Completed) LT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000562-38 Sponsor Protocol Number: BCBe/03/Pan-CPI/002 Start Date*: 2010-04-20
    Sponsor Name:Berlin-Chemie AG
    Full Title: RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A GASTRO-RESISTANT FILM-COATED PANCREATIN TABLET FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WI...
    Medical condition: The purpose of this trial is to evaluate the clinical efficacy and safety of a gastro-resistant film-coated tablet in comparison to placebo in the treatment of pancreatic exocrine insufficiency due...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10033628 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003011-12 Sponsor Protocol Number: RR08/8613 Start Date*: 2009-03-30
    Sponsor Name:University of Leeds
    Full Title: Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002584-90 Sponsor Protocol Number: D1511C00002 Start Date*: 2005-08-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD8309 on Airway Inflammation as Assessed in Induced Spu...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000047-18 Sponsor Protocol Number: C-1808 Start Date*: 2004-07-27
    Sponsor Name:Biogen Idec Ltd.
    Full Title: An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803.
    Medical condition: Male and female subjects with multiple sclerosis who have completed natalizumab studies C-1801, C-1802, or C-1803
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007764-14 Sponsor Protocol Number: XTL B07-002 Start Date*: 2008-06-09
    Sponsor Name:XTL Development Inc.
    Full Title: An Open-label 52-Week Safety Study of Bicifadine SR in Adult Outpatients with Chronic Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
    Medical condition: Chronic neuropathic pain in patients with diabetic peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-010660-42 Sponsor Protocol Number: ORA2 Start Date*: 2009-08-13
    Sponsor Name:BOWS Pharmaceuticals AG
    Full Title: A double-blind two part placebo-controlled study consisting of a single ascending and multiple-dose tolerance study of peroral insulin in patients with Type 2 diabetes
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023101-35 Sponsor Protocol Number: CJI-202 Start Date*: 2011-02-11
    Sponsor Name:Sequel Pharmaceuticals Inc.
    Full Title: TUNDRA-AF: A mulTi-center, randomized, doUble-bliNded, placebo-controlled Dose-escalating study of the effects of K201 on the RestorAtion of sinus rhythm in subjects with symptomatic Atrial Fibri...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000057-44 Sponsor Protocol Number: MW2008-09-03 Start Date*: 2013-09-05
    Sponsor Name:Mediwound Ltd
    Full Title: Feasibility Study: Enzymatic Debridement in Patients (Adults) with Partial Thickness and Full Thickness Burns - Protocol MW 2008-09-03
    Medical condition: Eschar removal from partial thickness and full thickness burns
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002856-33 Sponsor Protocol Number: ALN-TTRSC-002 Start Date*: 2013-11-15
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients with Transthyretin (TTR) Cardiac Amyloidosis
    Medical condition: Transthyretin (TTR) Cardiac Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 56  57  58  59  60  61  62  63  64  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 19:33:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA